Piper Jaffray Companies Increases Halozyme Therapeutics, Inc. (HALO) Price Target to $29.00
Halozyme Therapeutics, Inc. (NASDAQ:HALO) had its price objective increased by Piper Jaffray Companies from $26.00 to $29.00 in a research note published on Monday morning, Marketbeat Ratings reports. Piper Jaffray Companies currently has an overweight rating on the biopharmaceutical company’s stock.
HALO has been the topic of several other research reports. Zacks Investment Research upgraded shares of Halozyme Therapeutics from a hold rating to a buy rating and set a $19.00 target price on the stock in a report on Wednesday, September 27th. BidaskClub upgraded shares of Halozyme Therapeutics from a sell rating to a hold rating in a report on Saturday, August 26th. Canaccord Genuity set a $16.00 price objective on shares of Halozyme Therapeutics and gave the stock a buy rating in a report on Wednesday, July 26th. BMO Capital Markets boosted their price objective on shares of Halozyme Therapeutics from $14.00 to $15.00 and gave the stock a market perform rating in a report on Friday, September 15th. Finally, Deutsche Bank AG boosted their price objective on shares of Halozyme Therapeutics to $20.00 and gave the stock a buy rating in a report on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $17.00.
Halozyme Therapeutics (HALO) opened at 17.77 on Monday. Halozyme Therapeutics has a 12-month low of $8.18 and a 12-month high of $17.92. The stock’s market cap is $2.38 billion. The company has a 50-day moving average price of $16.07 and a 200 day moving average price of $13.85.
Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. The business had revenue of $33.80 million for the quarter, compared to analyst estimates of $31.76 million. The business’s revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.21) EPS. On average, equities research analysts predict that Halozyme Therapeutics will post ($0.13) EPS for the current year.
WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/piper-jaffray-companies-increases-halozyme-therapeutics-inc-halo-price-target-to-29-00/1643153.html.
Hedge funds have recently modified their holdings of the business. Ameritas Investment Partners Inc. acquired a new position in Halozyme Therapeutics in the 1st quarter worth $122,000. Teacher Retirement System of Texas acquired a new position in Halozyme Therapeutics in the 2nd quarter worth $129,000. Arrowstreet Capital Limited Partnership acquired a new position in Halozyme Therapeutics in the 2nd quarter worth $131,000. Prudential Financial Inc. lifted its holdings in Halozyme Therapeutics by 8.7% in the 2nd quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 940 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Halozyme Therapeutics in the 2nd quarter worth $171,000. Hedge funds and other institutional investors own 85.06% of the company’s stock.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.